Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASN002 Dose Escalation in Atopic Dermatitis
NCT03139981Phase 1Completed
- Sponsor
- Asana BioSciences, LLC
- Start
- Apr 2017
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of gusacitinib in atopic dermatitis (AD) (4 arms), sponsored by Asana BioSciences, LLC. Primary endpoint: Maximum Tolerated Dose at 43 days. Started Apr 2017; status: completed.
02
Drugs
gusacitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03139981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03139981.